Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fludarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL5329821 | 0.92 | CA5A (0.73) | NT5ELMNAHIF1ACA5AADORA1 | |
| Fludarabine Phosphate SCHEMBL4744004 | 0.92 | CA5A (0.73) | NT5ELMNAHIF1ACA5AADORA1 | |
| Fludarabine Phosphate SCHEMBL28198534 | 0.88 | CA5A (0.78) | NT5ELMNAHIF1ACA5AADORA1 | |
| Fludarabine Phosphate SCHEMBL28199095 | 0.87 | CA5A (0.77) | NT5ELMNAHIF1ACA5AADORA1 | |
| Fludarabine SCHEMBL12232219 | 0.86 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL13046076 | 0.86 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL3047091 | 0.86 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL13046078 | 0.86 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL12018226 | 0.86 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL5505924 | 0.86 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672951-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3668516-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND A DICARBOXYLIC ACID | Merck Patent GmbH (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038214-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019034673-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND A DICARBOXYLIC ACID | MERCK PATENT GMBH (DE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2016038534-A1 | FENRETINIDE COMPLEXES | ISTITUTI FISIOTERAPICI OSPITALIERI (IFO) - ISTITUTO REGINA ELENA PER LO STUDIO E LA CURA DEI TUMORI (IT) | 2016-03-17 | — | — | WO | disclosed |
| EP-2994471-A1 | MACROCYCLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2013110309-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-01 | — | — | WO | disclosed |
| EP-2575792-A1 | BIGUANIDE COMPOUNDS AND ITS USE FOR TREATING CANCER | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011147528-A1 | BIGUANIDE COMPOUNDS AND ITS USE FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | WO | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2367821-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |